drugset
drugset / Trial / NCT05493800

Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT

NCT05493800 ↗

Phase 2 Unknown 60 enrolled MitoImmune Therapeutics
RandomizedSequentialQuadruple-blindPrevention

Summary

Evaluate the efficacy and safety for the prevention of oral mucositis and PK of MIT-001 for lymphoma or multiple myeloma patients receiving conditioning chemotherapy for autologous hematopoietic stem cell transplantation(auto-HSCT).

Timeline

Start
2022-02-01
Primary completion
2024-06-30
Completion
2024-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject MIT-001 Unknown 5 mg Intravenous
Subject MIT-001 Unknown 10 mg Intravenous
Subject MIT-001 Unknown 20 mg Intravenous

Indications

chemotherapy-induced oral mucositis plasma cell myeloma